Sunshine Biopharma, Inc.

SBFM

US8677816014

Pharmaceuticals

End-of-day quote Nasdaq Other stock markets 03:30:00 15/05/2024 am IST			5-day change	1st Jan Change
0.8924 ^USD	-0.79%		-9.86%	-96.71%

13/05	Certain Common Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-MAY-2024.	CI
19/04	Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product	MT

Sunshine Biopharma, Inc. authorizes a Buyback Plan.

January 19, 2023

The Board of Directors of Sunshine Biopharma, Inc. has authorized a buyback plan on January 19, 2023.

Latest news about Sunshine Biopharma, Inc.

Certain Common Stock of Sunshine Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 13-MAY-2024.	13/05	CI
Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product	19/04	MT
Top Premarket Decliners	19/04	MT
Sunshine Biopharma Shares Slump After Reverse Stock Split Announcement	12/04	MT
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023.	29/03	CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Sunshine Biopharma, Inc. announced that it has received $5 million in funding	28/03	CI
Sunshine Biopharma, Inc. announced that it expects to receive $0.01 million in funding	04/03	CI
Sunshine Biopharma, Inc. Announces Executive Changes	30/01	CI
Sunshine Biopharma, Inc. Announces Move Its Headquarters to New York City	04/12	CI
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023.	13/11	CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Jewish General Hospital Announces Termination of the Research Agreement with Sunshine Biopharma, Inc	02/11	CI
Sunshine Biopharma Gets Extension to Comply With Nasdaq Minimum Bid Price Rule	22/23/22	MT
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023.	11/23/11	CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Aegis Capital Initiates Sunshine Biopharma at Buy Rating With $2.60	07/23/07	MT
Sunshine Biopharma, Inc. announced that it has received CAD 5 million in funding	16/23/16	CI
Wall Street Set to Open Higher; Import Prices Rebound More Than Expected	12/23/12	MT
Sunshine Biopharma, Inc. announced that it expects to receive CAD 5 million in funding	12/23/12	CI
Tranche Update on Sunshine Biopharma, Inc.'s Equity Buyback Plan announced on January 19, 2023.	11/23/11	CI
Sunshine Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Sunshine Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	04/23/04	CI
Sunshine Biopharma, Inc. Signs Exclusive Worldwide License with University of Arizona for PLpro-Based Covid-19 Treatment	28/23/28	CI
Sector Update: Health Care Stocks Rise on Friday	11/23/11	MT

Chart Sunshine Biopharma, Inc.

Duration

Period

More charts

Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The Company offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The Company has 27 additional generic prescription drugs. In addition, the Company is engaged in the development of various proprietary drugs, including Adva-27a, K1.1 mRNA and SBFM-PL4. Adva-27a is a small chemotherapy molecule targeting pancreatic cancer. The K1.1 mRNA is developed for liver cancer. SBFM-PL4 is an anti-coronavirus compound. The Company operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). It also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio consisting of 50 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.

Sector

Pharmaceuticals

Calendar

31/07/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Sunshine Biopharma, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.89 USD

Average target price

15 USD

Spread / Average Target

+1,585.39%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUNSHINE BIOPHARMA, INC.	-96.71%	888K
ELI LILLY AND COMPANY	+32.36%	709B
NOVO NORDISK A/S	+30.77%	595B
JOHNSON & JOHNSON	-1.60%	367B
MERCK & CO., INC.	+20.07%	334B
ABBVIE INC.	+6.04%	289B
ASTRAZENECA PLC	+14.77%	239B
NOVARTIS AG	+9.13%	211B
ROCHE HOLDING AG	-3.97%	203B
AMGEN INC.	+9.27%	171B

Other Pharmaceuticals